ReviewJournal of clinical immunology2010
IVIG treatment and prognosis in Guillain-Barré syndrome.
Review in Journal of clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 113 citations in OpenAlex.
- Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial.Critical care (London, England) · 2013Trial
- Efgartigimod-responsive autoimmune peripheral neuropathy with concurrent anti-GM2 IgG and anti-contactin-1 IgG antibodies: a rare case report.BMC neurology · 2026Article
- A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy.Frontiers in immunology · 2026Article
- Triple Vessel Disease With Intracranial Hemorrhage in a Patient With Guillain-Barre Syndrome: A Potential Complication, a Coincidental Finding or a Treatment-Related Adverse Event.Clinical case reports · 2025Article
- Guillain-Barré Syndrome in war-torn regions: the forgotten neurological emergency in humanitarian crises.Annals of medicine and surgery (2012) · 2025Article
- Recurrent Guillain-Barré Syndrome Following Ischemic Stroke: A Rare Case With a Four-Year Inter-Episode Interval.Cureus · 2025Article
- Article
- Article
- Review
- Postpartum Guillain-Barré syndrome: a case report.Annals of medicine and surgery (2012) · 2023Article
- Intravenous immunoglobulin treatment with prognosis for the first six months of Guillain-Barré Syndrome in Somalia: Case series.Annals of medicine and surgery (2012) · 2022Article
- Controversies in neuroimmunology: multiple sclerosis, vaccination, SARS-CoV-2 and other dilemasBiomedica : revista del Instituto Nacional de Salud · 2022Article
- Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome.Clinical pharmacokinetics · 2022Article
- Article
- Pathogenic TNF-α drives peripheral nerve inflammation in an Aire-deficient model of autoimmunity.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Axonal variants of Guillain-Barré syndrome: an update.Journal of neurology · 2021Review
- Article
- Therapeutic plasma exchange as a first-choice therapy for axonal Guillain-Barré syndrome: A case-based review of the literature (Review).Experimental and therapeutic medicine · 2021Review
- Intensive Care and Treatment of Severe Guillain-Barré Syndrome.Frontiers in pharmacology · 2021Review
- Changes of Serum IgG Dimer Levels after Treatment with IVIg in Guillain-Barré Syndrome.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGuillain-Barré syndrome (GBS) is an acute, immune-mediated polyneuropathy that often leads to severe weakness. Intravenous immunoglobulin (IVIG) is a proven effective treatment for GBS (class 1 evidence). However, about 25% of patients need artificial ventilation and 20% are still unable to walk unaided after 6 months. Important clinical factors associated with poor outcome are age, presence of preceding diarrhea and the severity of disability in the early course of disease. These clinical factors were combined in a clinical prognostic scoring scale, the Erasmus GBS Outcome Scale (EGOS). MATERIALS AND
methodsGBS patients being unable to walk unaided are currently treated with a standard single IVIg dose (0.4 g/kg bodyweight for 5 days). A recent retrospective study in 174 GBS patients enrolled in one of our randomized controlled clinical trials showed that patients with a minor increase of serum IgG level after standard single IVIg dose recovered significantly slower. Additionally, fewer patients reached the ability to walk unaided at six months after correction for the known clinical prognostic factors (multivariate analysis; P < 0.022). DISCUSSION: It is yet unknown why some GBS patients only have a minor increase after standard IVIg treatment. By using the EGOS it is possible to select GBS patients with a poor prognosis. These patients potentially may benefit from a second IVIg dose.
conclusionA standard dose of IVIG is not sufficiently effective in many GBS patients. Whether these patients might benefit from a second IVIg dose needs further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.